<p>Strs Ohio 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在 ResMed Inc.（纽约证券交易所代码：RMD - 免费报告）的持股削减了 89.7%。该公司在此期间出售了 30,494 股后，持有 3,497 股该医疗设备提供商的股票。Strs Ohio 在 ResMed 的持股在最近一个季度末价值 842,000 美元。</p>
<ul>
<li>HCA Healthcare 反弹：减肥药真的构成重大威胁吗？</li>
</ul>
<p>其他几家对冲基金也买卖了 RMD 的股票。Jones Financial Companies Lllp 在第一季度将其在 ResMed 的持股增加了 52.6%。Jones Financial Companies Lllp 目前持有 2,882 股该医疗设备提供商的股票，价值 645,000 美元，此前在上个季度购买了额外的 994 股。Arrowstreet Capital Limited Partnership 在第二季度获得了 ResMed 的新头寸，价值 389,000 美元。Brown Advisory Inc. 在第二季度将其在 ResMed 的持股增加了 17.8%。Brown Advisory Inc. 目前持有 1,586 股该医疗设备提供商的股票，价值 409,000 美元，此前在此期间购买了额外的 240 股。Cresset Asset Management LLC 在第二季度获得了 ResMed 的新头寸，价值 206,000 美元。最后，Alliancebernstein L.P. 在第二季度将其在 ResMed 的持股增加了 24.2%。Alliancebernstein L.P. 目前持有 286,078 股该医疗设备提供商的股票，价值 73,808,000 美元，此前在此期间购买了额外的 55,790 股。对冲基金和其他机构投资者持有该公司 54.98% 的股票。</p>
<h2>内部人士下注</h2>
<p>在其他 ResMed 的新闻中，董事 Peter C. Farrell 于 4 月 1 日星期三出售了 2,000 股公司的股票。股票以平均价格 225.00 美元出售，总交易额为 450,000.00 美元。该交易在与证券交易委员会的法律文件中披露，可以通过此链接访问。此外，首席执行官 Michael J. Farrell 于 2 月 9 日星期一出售了 4,991 股公司的股票。股票以平均价格 273.78 美元出售，总交易额为 1,366,435.98 美元。交易后，首席执行官持有 466,223 股公司的股票，价值 127,642,532.94 美元。这代表其持股减少了 1.06%。该销售的披露在 SEC 文件中可用。在过去 90 天内，内部人士已出售价值 4,715,237 美元的 18,973 股公司股票。目前公司内部人士持有 0.65% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>几位股票分析师最近对该股票发布了报告。花旗集团在 4 月 9 日星期四的研究报告中将 ResMed 的目标价格从 345.00 美元下调至 340.00 美元，并对该公司给予了 “买入” 评级。KeyCorp 在 4 月 27 日星期一的研究报告中将 ResMed 的目标价格从 302.00 美元下调至 290.00 美元，并对该公司给予了 “增持” 评级。Evercore 在 4 月 13 日星期一的研究报告中设定了 255.00 美元的目标价格，并给予该公司 “跑赢大盘” 评级。摩根大通在 4 月 15 日星期三的研究报告中开始覆盖 ResMed 的股票，并对该公司给予了 “增持” 评级。最后，华尔街 Zen 在 3 月 14 日星期六的研究报告中将 ResMed 的评级从 “买入” 下调至 “持有”。一位研究分析师对该股票给予了强烈买入评级，九位分析师给予了买入评级，五位分析师对该股票给予了持有评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价格为 286.18 美元。</p>
<p><strong>查看我们对 ResMed 的最新分析</strong></p>
<h2>ResMed 股票表现</h2>
<p>纽约证券交易所代码：RMD 周五开盘价为 206.83 美元。该公司的债务与股本比率为 0.06，速动比率为 2.33，流动比率为 3.01。该公司的 50 日移动平均线为 230.41 美元，200 日移动平均线为 245.04 美元。该股票的市值为 301.3 亿美元，市盈率为 19.94，市盈增长比率为 1.34，贝塔值为 0.84。ResMed Inc. 的 52 周低点为 198.64 美元，52 周高点为 293.81 美元。</p>
<p>ResMed（纽约证券交易所代码：RMD - 获取免费报告）最近于 4 月 30 日星期四发布了季度财报。该医疗设备提供商报告本季度每股收益为 2.86 美元，超出分析师的共识预期 2.79 美元，超出 0.07 美元。该公司本季度的收入为 14.3 亿美元，而分析师的预期为 14.2 亿美元。ResMed 的净利润率为 27.44%，股本回报率为 25.35%。该公司的季度收入同比增长 10.8%。在去年同期，该公司每股收益为 2.37 美元。整体而言，研究分析师预测 ResMed Inc. 本财年将发布 11.13 美元的每股收益。</p>
<h2>ResMed 分红公告</h2>
<p>该公司最近还披露了一项季度分红，将于 6 月 18 日星期四支付。5 月 14 日星期四的股东将获得每股 0.60 美元的分红。除息日为 5 月 14 日星期四。这代表每年 2.40 美元的分红，收益率为 1.2%。ResMed 的分红支付比率目前为 23.14%。</p>
<h2>ResMed 公司简介</h2>
<p>（免费报告）</p>
<p>ResMed NYSE: RMD 是一家全球医疗设备和云连接公司，专注于改善患有睡眠呼吸障碍和慢性呼吸疾病的人的健康结果。公司成立于 1989 年，总部位于加利福尼亚州圣地亚哥，开发、制造和分销一系列设备和软件，供全球的患者、临床医生和提供者使用。</p>
<p>瑞思迈的产品组合以非侵入性通气和睡眠治疗设备为中心，包括持续正压呼吸器（CPAP）和双水平设备、面罩及相关配件，用于治疗阻塞性睡眠呼吸暂停和其他呼吸系统疾病。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在瑞思迈吗？</h2>
<p>在考虑瑞思迈之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而瑞思迈并不在名单上。</p>
<p>尽管瑞思迈目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

瑞思迈

标普医疗保健服务 ETF - SPDR

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>Strs Ohio 在第四季度将其在瑞思迈（ResMed Inc.，NYSE:RMD）的持股减少了 89.7%，在出售了 30,494 股后，持有 3,497 股。其他对冲基金也调整了其头寸，琼斯金融（Jones Financial）将其持股增加了 52.6%。内部人士在过去 90 天内出售了总计 470 万美元的股票。分析师们设定了新的价格目标，花旗集团将其目标下调至 340 美元，KeyCorp 则下调至 290 美元。瑞思迈的股票开盘价为 206.83 美元，市值为 301.3 亿美元，市盈率为 19.94。该公司报告每股收益为 2.86 美元，超出预期</p>

<p>Strs Ohio trimmed its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 89.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,497 shares of the medical equipment provider's stock after selling 30,494 shares during the period. Strs Ohio's holdings in ResMed were worth $842,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Strs Ohio 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在 ResMed Inc.（纽约证券交易所代码：RMD - 免费报告）的持股削减了 89.7%。该公司在此期间出售了 30,494 股后，持有 3,497 股该医疗设备提供商的股票。Strs Ohio 在 ResMed 的持股在最近一个季度末价值 842,000 美元。</p>
</div><ul>
<li>HCA Healthcare Rallies: Weight-loss drugs really a big threat?</li>
</ul>
<div class="lb-trans"><ul>
<li>HCA Healthcare 反弹：减肥药真的构成重大威胁吗？</li>
</ul>
</div><p>Several other hedge funds have also bought and sold shares of RMD. Jones Financial Companies Lllp increased its holdings in shares of ResMed by 52.6% during the 1st quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider's stock valued at $645,000 after purchasing an additional 994 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of ResMed in the 2nd quarter valued at $389,000. Brown Advisory Inc. lifted its stake in shares of ResMed by 17.8% in the 2nd quarter. Brown Advisory Inc. now owns 1,586 shares of the medical equipment provider's stock valued at $409,000 after purchasing an additional 240 shares during the period. Cresset Asset Management LLC acquired a new position in shares of ResMed in the 2nd quarter valued at $206,000. Finally, Alliancebernstein L.P. lifted its stake in shares of ResMed by 24.2% in the 2nd quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider's stock valued at $73,808,000 after purchasing an additional 55,790 shares during the period. Hedge funds and other institutional investors own 54.98% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金也买卖了 RMD 的股票。Jones Financial Companies Lllp 在第一季度将其在 ResMed 的持股增加了 52.6%。Jones Financial Companies Lllp 目前持有 2,882 股该医疗设备提供商的股票，价值 645,000 美元，此前在上个季度购买了额外的 994 股。Arrowstreet Capital Limited Partnership 在第二季度获得了 ResMed 的新头寸，价值 389,000 美元。Brown Advisory Inc. 在第二季度将其在 ResMed 的持股增加了 17.8%。Brown Advisory Inc. 目前持有 1,586 股该医疗设备提供商的股票，价值 409,000 美元，此前在此期间购买了额外的 240 股。Cresset Asset Management LLC 在第二季度获得了 ResMed 的新头寸，价值 206,000 美元。最后，Alliancebernstein L.P. 在第二季度将其在 ResMed 的持股增加了 24.2%。Alliancebernstein L.P. 目前持有 286,078 股该医疗设备提供商的股票，价值 73,808,000 美元，此前在此期间购买了额外的 55,790 股。对冲基金和其他机构投资者持有该公司 54.98% 的股票。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total transaction of $450,000.00. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Michael J. Farrell sold 4,991 shares of the company's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $273.78, for a total transaction of $1,366,435.98. Following the transaction, the chief executive officer owned 466,223 shares of the company's stock, valued at $127,642,532.94. This represents a 1.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 18,973 shares of company stock valued at $4,715,237 over the last 90 days. 0.65% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 ResMed 的新闻中，董事 Peter C. Farrell 于 4 月 1 日星期三出售了 2,000 股公司的股票。股票以平均价格 225.00 美元出售，总交易额为 450,000.00 美元。该交易在与证券交易委员会的法律文件中披露，可以通过此链接访问。此外，首席执行官 Michael J. Farrell 于 2 月 9 日星期一出售了 4,991 股公司的股票。股票以平均价格 273.78 美元出售，总交易额为 1,366,435.98 美元。交易后，首席执行官持有 466,223 股公司的股票，价值 127,642,532.94 美元。这代表其持股减少了 1.06%。该销售的披露在 SEC 文件中可用。在过去 90 天内，内部人士已出售价值 4,715,237 美元的 18,973 股公司股票。目前公司内部人士持有 0.65% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several equities analysts recently issued reports on the stock. Citigroup decreased their target price on shares of ResMed from $345.00 to $340.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, April 9th. KeyCorp decreased their target price on shares of ResMed from $302.00 to $290.00 and set an &#34;overweight&#34; rating for the company in a research note on Monday, April 27th. Evercore set a $255.00 target price on shares of ResMed and gave the company an &#34;outperform&#34; rating in a research note on Monday, April 13th. JPMorgan Chase &amp; Co. assumed coverage on shares of ResMed in a research note on Wednesday, April 15th. They issued an &#34;overweight&#34; rating for the company. Finally, Wall Street Zen cut shares of ResMed from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $286.18.</p>
<div class="lb-trans"><p>几位股票分析师最近对该股票发布了报告。花旗集团在 4 月 9 日星期四的研究报告中将 ResMed 的目标价格从 345.00 美元下调至 340.00 美元，并对该公司给予了 “买入” 评级。KeyCorp 在 4 月 27 日星期一的研究报告中将 ResMed 的目标价格从 302.00 美元下调至 290.00 美元，并对该公司给予了 “增持” 评级。Evercore 在 4 月 13 日星期一的研究报告中设定了 255.00 美元的目标价格，并给予该公司 “跑赢大盘” 评级。摩根大通在 4 月 15 日星期三的研究报告中开始覆盖 ResMed 的股票，并对该公司给予了 “增持” 评级。最后，华尔街 Zen 在 3 月 14 日星期六的研究报告中将 ResMed 的评级从 “买入” 下调至 “持有”。一位研究分析师对该股票给予了强烈买入评级，九位分析师给予了买入评级，五位分析师对该股票给予了持有评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价格为 286.18 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on ResMed</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ResMed 的最新分析</strong></p>
</div><h2>ResMed Stock Performance</h2>
<div class="lb-trans"><h2>ResMed 股票表现</h2>
</div><p>NYSE:RMD opened at $206.83 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. The company has a fifty day moving average of $230.41 and a two-hundred day moving average of $245.04. The stock has a market capitalization of $30.13 billion, a PE ratio of 19.94, a P/E/G ratio of 1.34 and a beta of 0.84. ResMed Inc. has a fifty-two week low of $198.64 and a fifty-two week high of $293.81.</p>
<div class="lb-trans"><p>纽约证券交易所代码：RMD 周五开盘价为 206.83 美元。该公司的债务与股本比率为 0.06，速动比率为 2.33，流动比率为 3.01。该公司的 50 日移动平均线为 230.41 美元，200 日移动平均线为 245.04 美元。该股票的市值为 301.3 亿美元，市盈率为 19.94，市盈增长比率为 1.34，贝塔值为 0.84。ResMed Inc. 的 52 周低点为 198.64 美元，52 周高点为 293.81 美元。</p>
</div><p>ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, topping analysts' consensus estimates of $2.79 by $0.07. The company had revenue of $1.43 billion during the quarter, compared to analysts' expectations of $1.42 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The firm's revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.37 earnings per share. As a group, research analysts forecast that ResMed Inc. will post 11.13 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>ResMed（纽约证券交易所代码：RMD - 获取免费报告）最近于 4 月 30 日星期四发布了季度财报。该医疗设备提供商报告本季度每股收益为 2.86 美元，超出分析师的共识预期 2.79 美元，超出 0.07 美元。该公司本季度的收入为 14.3 亿美元，而分析师的预期为 14.2 亿美元。ResMed 的净利润率为 27.44%，股本回报率为 25.35%。该公司的季度收入同比增长 10.8%。在去年同期，该公司每股收益为 2.37 美元。整体而言，研究分析师预测 ResMed Inc. 本财年将发布 11.13 美元的每股收益。</p>
</div><h2>ResMed Dividend Announcement</h2>
<div class="lb-trans"><h2>ResMed 分红公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Shareholders of record on Thursday, May 14th will be given a dividend of $0.60 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a yield of 1.2%. ResMed's dividend payout ratio is currently 23.14%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项季度分红，将于 6 月 18 日星期四支付。5 月 14 日星期四的股东将获得每股 0.60 美元的分红。除息日为 5 月 14 日星期四。这代表每年 2.40 美元的分红，收益率为 1.2%。ResMed 的分红支付比率目前为 23.14%。</p>
</div><h2>ResMed Company Profile</h2>
<div class="lb-trans"><h2>ResMed 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.</p>
<div class="lb-trans"><p>ResMed NYSE: RMD 是一家全球医疗设备和云连接公司，专注于改善患有睡眠呼吸障碍和慢性呼吸疾病的人的健康结果。公司成立于 1989 年，总部位于加利福尼亚州圣地亚哥，开发、制造和分销一系列设备和软件，供全球的患者、临床医生和提供者使用。</p>
</div><p>ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.</p>
<div class="lb-trans"><p>瑞思迈的产品组合以非侵入性通气和睡眠治疗设备为中心，包括持续正压呼吸器（CPAP）和双水平设备、面罩及相关配件，用于治疗阻塞性睡眠呼吸暂停和其他呼吸系统疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than ResMed</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=RMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in ResMed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在瑞思迈吗？</h2>
</div><p>Before you consider ResMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑瑞思迈之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而瑞思迈并不在名单上。</p>
</div><p>While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管瑞思迈目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ResMed Inc. $RMD Shares Sold by Strs Ohio

Market Beat

HCA控股

AllianceBernstein

花旗

科凯国际

Evercore

摩根大通

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

CITIGROUP INC 6.250 NON CUM SER II PFD WI

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

瑞思迈公司 $RMD 的股票被俄亥俄州教师退休系统出售